Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts

[1]  T. Fujimori,et al.  IL-22 produced by cancer-associated fibroblasts promotes gastric cancer cell invasion via STAT3 and ERK signaling , 2014, British Journal of Cancer.

[2]  C. Porta,et al.  Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..

[3]  Craig E. Higgins,et al.  SERPINE1: A Molecular Switch in the Proliferation-Migration Dichotomy in Wound-"Activated" Keratinocytes. , 2014, Advances in wound care.

[4]  J. She,et al.  Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of mycophenolic acid. , 2013, International journal of clinical and experimental pathology.

[5]  Y. Woo,et al.  Cancer-Associated Fibroblasts Promote Proliferation of Endometrial Cancer Cells , 2013, PloS one.

[6]  G. Gores,et al.  Liver Transplantation for Perihilar Cholangiocarcinoma , 2013, Digestive Diseases.

[7]  U. Neumann,et al.  Liver transplantation for intra- and extrahepatic cholangiocarcinoma. , 2013, Annals of transplantation.

[8]  F. Jerhammar,et al.  Cancer-Associated Fibroblasts Induce Matrix Metalloproteinase–Mediated Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cells , 2012, Molecular Cancer Research.

[9]  R. Puri,et al.  IL‐13 regulates cancer invasion and metastasis through IL‐13Rα2 via ERK/AP‐1 pathway in mouse model of human ovarian cancer , 2012, International journal of cancer.

[10]  W. V. van IJcken,et al.  Metabolic enzyme IMPDH is also a transcription factor regulated by cellular state. , 2012, Molecular cell.

[11]  J. Casal,et al.  High expression of IL-13 receptor α2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. , 2012, Cancer research.

[12]  H. Lenz,et al.  Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis , 2012, British Journal of Cancer.

[13]  Y. Zhang,et al.  Interleukin-8 induces the endothelial cell migration through the Rac 1/RhoA-p38MAPK pathway. , 2012, European review for medical and pharmacological sciences.

[14]  J. Darnell,et al.  The JAK-STAT pathway at twenty. , 2012, Immunity.

[15]  O. Franco,et al.  Targeting the tumor stroma as a novel therapeutic approach for prostate cancer. , 2012, Advances in pharmacology.

[16]  A. Mintz,et al.  IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications. , 2011, Translational oncology.

[17]  Z. Mujagic,et al.  Interleukin 13 expression in the primary breast cancer tumour tissue. , 2011, Biochemia medica.

[18]  D. Stocken,et al.  Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 , 2011, Cancer Immunology, Immunotherapy.

[19]  S. Brandt,et al.  Induction of TLR-2 and TLR-5 Expression by Helicobacter pylori Switches cagPAI-Dependent Signalling Leading to the Secretion of IL-8 and TNF-α , 2011, PloS one.

[20]  J. Dufour,et al.  Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma , 2011, Molecular Cancer Therapeutics.

[21]  T. Ishiko,et al.  Hepatic Stellate Cells Accelerate the Malignant Behavior of Cholangiocarcinoma Cells , 2011, Annals of Surgical Oncology.

[22]  Robert A. Weinberg,et al.  Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts , 2010, Proceedings of the National Academy of Sciences.

[23]  M. Acalovschi,et al.  Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. , 2010, Journal of gastrointestinal and liver diseases : JGLD.

[24]  S. Donnelly,et al.  Inflammation and cancer: macrophage migration inhibitory factor (MIF)—the potential missing link , 2010, QJM : monthly journal of the Association of Physicians.

[25]  J. Fellenberg,et al.  Overexpression of Inosine 5′-Monophosphate Dehydrogenase Type II Mediates Chemoresistance to Human Osteosarcoma Cells , 2010, PloS one.

[26]  Hai-rim Shin,et al.  Epidemiology of cholangiocarcinoma: An update focusing on risk factors , 2010, Cancer science.

[27]  A. Sutton,et al.  Monocyte chemoattractant protein‐1 (MCP‐1)/CCL2 secreted by hepatic myofibroblasts promotes migration and invasion of human hepatoma cells , 2009, International journal of cancer.

[28]  Fei Xing,et al.  Cancer associated fibroblasts (CAFs) in tumor microenvironment. , 2010, Frontiers in bioscience.

[29]  Y. Abiko,et al.  Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker , 2010, Molecular Cancer.

[30]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[31]  M. Miyazaki,et al.  Stromal MCP‐1 in mammary tumors induces tumor‐associated macrophage infiltration and contributes to tumor progression , 2009, International journal of cancer.

[32]  S. Ishikawa,et al.  Hepatic Stellate Cells May Relate to Progression of Intrahepatic Cholangiocarcinoma , 2009, Annals of Surgical Oncology.

[33]  T. Suthiphongchai,et al.  Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. , 2009, Oncology reports.

[34]  T. Okada,et al.  Rapamycin inhibits growth of cholangiocarcinoma cells. , 2009, Hepato-gastroenterology.

[35]  Derek Y. Chiang,et al.  Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.

[36]  W. Ansorge,et al.  Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid , 2008, Molecular Cancer Therapeutics.

[37]  M. Dai,et al.  Mycophenolic Acid Activation of p53 Requires Ribosomal Proteins L5 and L11* , 2008, Journal of Biological Chemistry.

[38]  Douglas B. Evans,et al.  Cancer-associated stromal fibroblasts promote pancreatic tumor progression. , 2008, Cancer research.

[39]  M. Andersson,et al.  Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer , 2008, International Journal of Clinical Oncology.

[40]  G. Gores,et al.  Cholangiocarcinoma: is transplantation an option? For whom? , 2007, Journal of hepatology.

[41]  L. Bernd,et al.  Prognostic significance of drug-regulated genes in high-grade osteosarcoma , 2007, Modern Pathology.

[42]  J. Járay,et al.  Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas. , 2007, Leukemia research.

[43]  J. Bernhagen,et al.  MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment , 2007, Nature Medicine.

[44]  F. Luppia,et al.  Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation , 2007 .

[45]  A. Mehrabi,et al.  Antifibrotic actions of mycophenolic acid , 2006, Clinical transplantation.

[46]  G. Kroemer,et al.  Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.

[47]  J. Shaughnessy,et al.  IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells , 2006, Molecular Cancer Therapeutics.

[48]  A. Allison.  Mechanisms of action of mycophenolate mofetil , 2005, Lupus.

[49]  Jeremy J. W. Chen,et al.  The role of interleukin-8 in cancer cells and microenvironment interaction. , 2005, Frontiers in bioscience : a journal and virtual library.

[50]  D. Jonas,et al.  Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy , 2005, BMC Cancer.

[51]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[52]  M. O. Moraes,et al.  Mycophenolate mofetil attenuates Walker's tumor growth when used alone, but the effect is lost when associated with cyclosporine. , 2004, Transplantation proceedings.

[53]  R. Abraham.  mTOR as a positive regulator of tumor cell responses to hypoxia. , 2004, Current topics in microbiology and immunology.

[54]  M. Manns,et al.  Clinical Pharmacokinetics of Everolimus , 2004, Clinical pharmacokinetics.

[55]  K. Shuai,et al.  Regulation of JAK–STAT signalling in the immune system , 2003, Nature Reviews Immunology.

[56]  Michael Bacher,et al.  Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma , 2003, International journal of cancer.

[57]  John David,et al.  Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[58]  M. Gonen,et al.  Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma , 2001, Annals of surgery.

[59]  E. Jaurrieta,et al.  Changing strategies in diagnosis and management of hilar cholangiocarcinoma , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[60]  E. Jaurrieta,et al.  Changing strategies in diagnosis and management of hilar cholangiocarcinoma , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[61]  J. Martorell.,et al.  Assessment of mycophenolic acid-induced immunosuppression: a new approach. , 2000, Clinical chemistry.

[62]  A. Allison,et al.  Mycophenolate mofetil and its mechanisms of action. , 2000, Immunopharmacology.

[63]  G. Gores,et al.  Prolonged disease‐free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[64]  T. Seufferlein,et al.  Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. , 1999, Cancer research.

[65]  J. Hickman,et al.  Cell cycle specific induction of HL-60 cell differentiation and apoptosis by mycophenolic acid , 1997, Cell Death and Differentiation.

[66]  K. Matsumoto,et al.  Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. , 1997, Cancer research.

[67]  M. Schreier,et al.  SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. , 1997, Transplantation.

[68]  K. Schupak,et al.  Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy , 1995, The British journal of surgery.

[69]  R. Tressler,et al.  Anti‐tumor activity of mycophenolate mofetil against human and mouse tumors in vivo , 1994, International journal of cancer.

[70]  G. Cunha,et al.  Role of stroma in oestrogen-induced epithelial proliferation. , 1992, Epithelial cell biology.

[71]  M. Gleave,et al.  Human prostate cancer model: Roles of growth factors and extracellular matrices , 1992, Journal of cellular biochemistry. Supplement.